Skip to main content
SpringerLink
Log in
Book cover

Multimodality Management of Borderline Resectable Pancreatic Cancer pp 289–306Cite as

The Role of Irreversible Electroporation and Other Ablative Techniques in Patients with Borderline Resectable Pancreatic Cancer

  • Chapter

  • 894 Accesses

Abstract

Initially diagnosed stage 3 (locally advanced) pancreatic adenocarcinoma (LAPC) remains an aggressive tumor with an overall poor prognosis (median survival of 9–12 months). Improvement in survival can be achieved in the small percentage that can undergo an R0 resection and in patients, where all macroscopic tumor can be cleared by local ablation techniques. Patients can have difficulty tolerating long durations of (>4–6 months) chemoradiotherapy, and this intervention alone still fails to prolong survival. Neoadjuvant treatment also has limited results on pain control or tumor downstaging since most current modalities do not shrink or downsize the tumor. In recent years, there has been a growing interest in the use of local ablative therapy for the treatment of non-resectable tumors in various organs. Ablation techniques are based on direct application of chemical, thermal, or electrical energy to a tumor, which leads to cellular necrosis without removal of the tumor. With ablation, both local control and relief from symptoms may be obtained in the majority of highly selected patients when appropriate technique is utilized. LAPC has been treated by various ablation techniques in the last few years with promising results. In this chapter, we will present the current status of local ablative therapies for the treatment of LAPC and discuss future trends.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, et al. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP. 2006;7:486–91.

    PubMed  Google Scholar 

  2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.

    Article  PubMed  Google Scholar 

  3. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.

    Article  PubMed  Google Scholar 

  4. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46.

    Article  PubMed  Google Scholar 

  5. Ghaneh P, Kawesha A, Howes N, Jones L, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. World J Surg. 1999;23:937–45.

    Article  CAS  PubMed  Google Scholar 

  6. Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 2011;4:11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  PubMed  Google Scholar 

  9. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–31.

    Article  CAS  PubMed  Google Scholar 

  10. Jurgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, Stolzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc. 2006;63:1059–62.

    Article  PubMed  Google Scholar 

  11. Goel R, Anderson K, Slaton J, Schmidlin F, Vercellotti G, Belcher J, et al. Adjuvant approaches to enhance cryosurgery. J Biomech Eng. 2009;131:074003.

    Article  PubMed  Google Scholar 

  12. Robinson D, Halperin N, Nevo Z. Two freezing cycles ensure interface sterilization by cryosurgery during bone tumor resection. Cryobiology. 2001;43:4–10.

    Article  CAS  PubMed  Google Scholar 

  13. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104:22–8.

    Article  PubMed  Google Scholar 

  14. Habash RW, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part III: ablation techniques. Crit Rev Biomed Eng. 2007;35:37–121.

    Article  PubMed  Google Scholar 

  15. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. HPB. 2010;12:348–51.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Goldberg SN, Mallery S, Gazelle GS, Brugge WR. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc. 1999;50:392–401.

    Article  CAS  PubMed  Google Scholar 

  17. Date RS, Biggins J, Paterson I, Denton J, McMahon RF, Siriwardena AK. Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma. Pancreas. 2005;30:266–71.

    Article  PubMed  Google Scholar 

  18. Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas. 2000;20:14–20.

    Article  CAS  PubMed  Google Scholar 

  19. Fegrachi S, Besselink MG, van Santvoort HC, van Hillegersberg R, Molenaar IQ. Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB. 2014;16:119–23.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010;97:220–5.

    Article  CAS  PubMed  Google Scholar 

  21. Spiliotis JD, Datsis AC, Michalopoulos NV, Kekelos SP, Vaxevanidou A, Rogdakis AG, et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg. 2007;392:55–60.

    Article  PubMed  Google Scholar 

  22. Wu Y, Tang Z, Fang H, Gao S, Chen J, Wang Y, et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol. 2006;94:392–5.

    Article  PubMed  Google Scholar 

  23. Singh V, Varshney S, Sewkani A, Varshney R, Deshpande G, Shaji P, Jat A. Radiofrequency ablation of unresectable pancreatic carcinoma: 10-year experience from single centre. Pancreatology. 2001;11(1):52.

    Google Scholar 

  24. Fegrachi S, Molenaar IQ, Klaessens JH, Besselink MG, Offerhaus JA, van Hillegersberg R. Radiofrequency ablation of the pancreas with and without intraluminal duodenal cooling in a porcine model. J Surg Res. 2013;184:867–72.

    Article  PubMed  Google Scholar 

  25. Cavallini M, La Torre M, Citone M, Rossi M, Rebonato A, Nava AK, et al. A novel approach in surgical palliation for unresectable pancreatic cancer with untreatable chronic pain: radiofrequency ablation of pancreatic mass and celiac plexus. Am Surg. 2010;76:E108–9.

    PubMed  Google Scholar 

  26. Martin RC, Scoggins CR, McMasters KM. Microwave hepatic ablation: initial experience of safety and efficacy. J Surg Oncol. 2007;96:481–6.

    Article  PubMed  Google Scholar 

  27. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17:171–8.

    Article  PubMed  Google Scholar 

  28. Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21:S192–203.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25 Suppl 1:S69–83.

    Article  PubMed  Google Scholar 

  30. Shock SA, Meredith K, Warner TF, Sampson LA, Wright AS, Winter 3rd TC, et al. Microwave ablation with loop antenna: in vivo porcine liver model. Radiology. 2004;231:143–9.

    Article  PubMed  Google Scholar 

  31. Wright AS, Lee Jr FT, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–83.

    Article  PubMed  Google Scholar 

  32. Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M, et al. Microwave ablation in locally advanced pancreatic carcinoma—a new look. Hepatogastroenterology. 2007;54:1305–10.

    CAS  PubMed  Google Scholar 

  33. Carrafiello G, Ierardi AM, Piacentino F, Lucchina N, Dionigi G, Cuffari S, et al. Microwave ablation with percutaneous approach for the treatment of pancreatic adenocarcinoma. Cardiovasc Intervent Radiol. 2012;35:439–42.

    Article  PubMed  Google Scholar 

  34. Dubinsky TJ, Cuevas C, Dighe MK, Kolokythas O, Hwang JH. High-intensity focused ultrasound: current potential and oncologic applications. AJR Am J Roentgenol. 2008;190:191–9.

    Article  PubMed  Google Scholar 

  35. He S. The noninvasive treatment of 251 cases of locally advanced pancreatic carcinoma—a new look. 2002.

    Google Scholar 

  36. Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol. 2001;27:1099–106.

    Article  CAS  PubMed  Google Scholar 

  37. Yuan CY, Yao C. Observation of high intensity focused ultrasound treating 40 cases of pancreatic cancer. Chin J Clin Hepatol. 2003;19:145–6.

    Google Scholar 

  38. Orgera G, Krokidis M, Monfardini L, Arnone P, Bonomo G, Della Vigna P, et al. Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in pancreatic metastasis from renal cell carcinoma. Cardiovasc Intervent Radiol. 2012;35:1258–61.

    Article  PubMed  Google Scholar 

  39. Orgera G, Monfardini L, Della Vigna P, Zhang L, Bonomo G, Arnone P, et al. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med. 2011;116:734–48.

    Article  CAS  PubMed  Google Scholar 

  40. Orgera G, Krokidis M, Monfardini L, Bonomo G, Della Vigna P, Fazio N, et al. High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. Cardiovasc Intervent Radiol. 2011;34:419–23.

    Article  PubMed  Google Scholar 

  41. Dunki-Jacobs EM, Philips P, Martin Ii RC. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg. 2014;101:1113–21.

    Article  CAS  PubMed  Google Scholar 

  42. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31.

    Article  CAS  PubMed  Google Scholar 

  43. Al-Sakere B, Andre F, Bernat C, Connault E, Opolon P, Davalos RV, et al. Tumor ablation with irreversible electroporation. PLoS One. 2007;2, e1135.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Granot Y, Rubinsky B. Mass transfer model for drug delivery in tissue cells with reversible electroporation. Int J Heat Mass Transf. 2008;51:5610–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Revilla-Vazquez AL. Electroporation as an efficient physical enhancer for skin drug delivery. J Clin Pharmacol. 2009;49:1262–83.

    Article  CAS  PubMed  Google Scholar 

  46. Prud’homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther. 2006;6:243–73.

    Article  PubMed  Google Scholar 

  47. Lee RC. Cell injury by electric forces. Ann N Y Acad Sci. 2005;1066:85–91.

    Article  CAS  PubMed  Google Scholar 

  48. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6:37–48.

    Article  PubMed  Google Scholar 

  49. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Bio-Med Eng. 2006;53:1409–15.

    Article  Google Scholar 

  50. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;6:307–12.

    Article  PubMed  Google Scholar 

  51. Dunki-Jacobs EM, Philips P, Martin 2nd RC. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg. 2014;218:179–87.

    Article  PubMed  Google Scholar 

  52. Martin 2nd RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012;215:361–9.

    Article  PubMed  Google Scholar 

  53. Martin 2nd RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20 Suppl 3:S443–9.

    Article  PubMed  Google Scholar 

  54. Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J vasc Interv Radiol. 2012;23:1613–21.

    Article  PubMed  Google Scholar 

  55. Philips P, Li Y, Li S, St. Hill CR, Martin RCG. Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model. Mol Ther Methods Clin Dev. 2015;2:12.

    Article  Google Scholar 

  56. Martin RC. Irreversible electroporation of locally advanced pancreatic head adenocarcinoma. J Gastrointest Surg. 2013;17:1850–6.

    Article  PubMed  Google Scholar 

  57. Martin RCG. Irreversible electroporation in locally advanced pancreatic adenocarcinoma of body/neck. J Gastro Oncol. 2015.

    Google Scholar 

  58. Martin RCG. Use of Irreversible electroporation in unresectable pancreatic cancer. HepatoBiliary Surg Nutr. 2015.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, University of Louisville, 315 E. Broadway—M10—Rm #312, Louisville, KY, 40202, USA

    Robert C. G. Martin II M.D., Ph.D. & Rachel O’Connor B.S.

Authors
  1. Robert C. G. Martin II M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel O’Connor B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. G. Martin II M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Matthew H.G. Katz

  2. Division of Surgical Oncology, The University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Syed A. Ahmad

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Martin, R.C.G., O’Connor, R. (2016). The Role of Irreversible Electroporation and Other Ablative Techniques in Patients with Borderline Resectable Pancreatic Cancer. In: Katz, M., Ahmad, S. (eds) Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22780-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22780-1_18

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22779-5

  • Online ISBN: 978-3-319-22780-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation